NCT07207928View on ClinicalTrials.gov

Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

February 21, 2025

Study Completion Date

September 16, 2026

Conditions

Urothelial Cancer

Trial Locations (1)

37134

Azienda Ospedaliera Universitaria Integrata di Verona, Verona

All Listed Sponsors

collaborator

Ospedale Mater Salutis-Legnago(Verona), Italy

UNKNOWN

collaborator

Casa di Cura Dott. Pederzoli

OTHER

lead

Azienda Ospedaliera Universitaria Integrata Verona

OTHER

NCT07207928 - Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer. | Biotech Hunter | Biotech Hunter